TEL AVIV, Israel--(BUSINESS WIRE)--Cardiosonic Ltd., a privately held company developing innovative and proprietary technology in the field of renal denervation (RDN) for the treatment of hypertension, announced the completion of patient enrollment in its first-in-man (FIM) TIVUS I clinical study. The study is designed to collect data on the safety and performance of the TIVUS™ System, a unique therapeutic ultrasound catheter system for the treatment of hypertension by renal denervation (RDN).
Help employers find you! Check out all the jobs and post your resume.